第 1 到 20 筆結果,共 20 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2023 | Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system | CHING-YAO YANG ; JIN-YUAN SHIH ; WEI-YU LIAO ; CHAO-CHI HO ; CHIA-LIN HSU ; TZU-HSIU TSAI ; SHANG-GIN WU ; YEN-TING LIN ; Hsu, Wei-Hsun; Jain, Suyog; Olsen, Steve; CHIH-HSIN YANG ; CHONG-JEN YU ; PAN-CHYR YANG | European journal of cancer (Oxford, England : 1990) | 0 | 0 | |
2 | 2017 | Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors | SHANG-GIN WU ; YIH-LEONG CHANG ; CHONG-JEN YU ; PAN-CHYR YANG ; JIN-YUAN SHIH | ERJ open research | 34 | 0 | |
3 | 2016 | The role of PIK3CA mutations among lung adenocarcinoma patients with primary and acquired resistance to EGFR tyrosine kinase inhibition | SHANG-GIN WU ; YIH-LEONG CHANG ; CHONG-JEN YU ; PAN-CHYR YANG ; JIN-YUAN SHIH | Scientific Reports | 35 | 28 | |
4 | 2016 | Association of BIM deletion polymorphism with intrinsic resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma | SHANG-GIN WU ; Liu Y.-N.; CHONG-JEN YU ; PAN-CHYR YANG ; JIN-YUAN SHIH | JAMA Oncology | 20 | 16 | |
5 | 2016 | The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients | SHANG-GIN WU ; Liu Y.-N.; Tsai M.-F.; YIH-LEONG CHANG ; CHONG-JEN YU ; PAN-CHYR YANG ; CHIH-HSIN YANG ; Wen Y.-F.; JIN-YUAN SHIH | Oncotarget | 207 | 191 | |
6 | 2016 | Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations | YEN-FU CHEN ; MIN-SHU HSIEH ; SHANG-GIN WU ; YIH-LEONG CHANG ; CHONG-JEN YU ; CHIH-HSIN YANG ; PAN-CHYR YANG ; JIN-YUAN SHIH | Journal of Thoracic Oncology | 63 | 51 | |
7 | 2014 | Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer | YEN-TING LIN ; YU-FEN WANG ; CHIH-HSIN YANG ; CHONG-JEN YU ; SHANG-GIN WU ; JIN-YUAN SHIH ; PAN-CHYR YANG | Journal of Thoracic Oncology | 50 | 38 | |
8 | 2014 | Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations | YEN-FU CHEN ; MIN-SHU HSIEH ; SHANG-GIN WU ; YIH-LEONG CHANG ; JIN-YUAN SHIH ; Liu Y.-N.; Tsai M.-F.; TZU-HSIU TSAI ; CHONG-JEN YU ; CHIH-HSIN YANG ; PAN-CHYR YANG | Journal of Thoracic Oncology | 69 | 64 | |
9 | 2013 | Survival of lung adenocarcinoma patients with malignant pleural effusion | SHANG-GIN WU ; CHONG-JEN YU ; Tsai M.-F.; WEI-YU LIAO ; CHIH-HSIN YANG ; I-SHIOW JAN ; PAN-CHYR YANG ; JIN-YUAN SHIH | European Respiratory Journal | 87 | 77 | |
10 | 2013 | Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis | SHANG-GIN WU ; Hu F.-C.; YIH-LEONG CHANG ; Lee Y.-C.; CHONG-JEN YU ; YEUN-CHUNG CHANG ; Wu J.-Y.; JIN-YUAN SHIH ; PAN-CHYR YANG | European Respiratory Journal | 35 | 36 | |
11 | 2012 | Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma | TZU-HSIU TSAI ; SHANG-GIN WU ; YIH-LEONG CHANG ; CHEN-TU WU ; Tsai M.-F.; Wei P.-F.; CHIH-HSIN YANG ; CHONG-JEN YU ; PAN-CHYR YANG ; JIN-YUAN SHIH | Journal of Thoracic Oncology | 22 | 26 | |
12 | 2012 | Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR | KUEI-PIN CHUNG ; SHANG-GIN WU ; Wu J.-Y.; CHIH-HSIN YANG ; CHONG-JEN YU ; Wei P.-F.; JIN-YUAN SHIH ; PAN-CHYR YANG | Clinical Cancer Research | 60 | 55 | |
13 | 2012 | EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with Wild-type EGFR | SHANG-GIN WU ; YAO-WEN KUO ; YIH-LEONG CHANG ; JIN-YUAN SHIH ; Chen Y.-H.; Tsai M.-F.; CHONG-JEN YU ; CHIH-HSIN YANG ; PAN-CHYR YANG | Journal of Thoracic Oncology | 90 | 72 | |
14 | 2012 | RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer | TZU-HSIU TSAI ; KANG-YI SU ; SHANG-GIN WU ; YIH-LEONG CHANG ; Luo S.-C.; Jane I.-S.; CHONG-JEN YU ; Yue S.-L.; JIN-YUAN SHIH ; PAN-CHYR YANG | European Respiratory Journal | 42 | 37 | |
15 | 2011 | Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations | SHANG-GIN WU ; CHIH-HSIN YANG ; CHONG-JEN YU ; JIH-HSIANG LEE ; Hsu Y.-C.; YIH-LEONG CHANG ; JIN-YUAN SHIH ; PAN-CHYR YANG | Lung Cancer | 41 | 35 | |
16 | 2008 | Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern | SHANG-GIN WU ; YIH-LEONG CHANG ; Hsu Y.-C.; Wu J.-Y.; CHIH-HSIN YANG ; CHONG-JEN YU ; Tsai M.-F.; JIN-YUAN SHIH ; PAN-CHYR YANG | Oncologist | 73 | 67 | |
17 | 2008 | Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma | SHANG-GIN WU ; Gow C.-H.; CHONG-JEN YU ; YIH-LEONG CHANG ; CHIH-HSIN YANG ; Hsu Y.-C.; JIN-YUAN SHIH ; Lee Y.-C.; PAN-CHYR YANG | European Respiratory Journal | 109 | 95 | |
18 | 2008 | Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response | Wu J.-Y.; SHANG-GIN WU ; CHIH-HSIN YANG ; Gow C.-H.; YIH-LEONG CHANG ; CHONG-JEN YU ; Shin J.-Y.; PAN-CHYR YANG | Clinical Cancer Research | 278 | 250 | |
19 | 2008 | First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer | Wu J.-Y.; CHONG-JEN YU ; CHIH-HSIN YANG ; SHANG-GIN WU ; Chiu Y.-H.; Gow C.-H.; YEUN-CHUNG CHANG ; Hsu Y.-C.; Wei P.-F.; JIN-YUAN SHIH ; PAN-CHYR YANG | American Journal of Respiratory and Critical Care Medicine | 69 | 62 | |
20 | 2008 | Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation | SHANG-GIN WU ; JIN-YUAN SHIH ; CHONG-JEN YU ; PAN-CHYR YANG | Journal of Thoracic Oncology | 11 | 9 |